Key Highlights

  • Acadia Pharmaceuticals (NASDAQ:ACAD) reported third-quarter GAAP Revenue of USD 342 million, up 23% from USD 279 million, and up 22% against non-GAAP adjusted revenue of USD 281 million a year earlier.
  • DAYBUE net sales reached USD 140 million, up 39% from USD 101 million, and NUPLAZID net sales were USD 202 million, up 14% on a GAAP basis and 12% on an adjusted basis.
  • Net income was USD 54 million, or USD 0.31 per diluted share, compared with USD 72 million, or USD 0.42, in the same quarter of 2025.
  • Full-year DAYBUE net sales guidance rose to USD 505 to 520 million from USD 480 to 510 million, while the total revenue range narrowed to USD 1.265 to 1.295 billion.

DAYBUE STIX Uptake Powers a 22% Adjusted Revenue Gain

Acadia Pharmaceuticals (NASDAQ:ACAD) released third-quarter results on November 4, 2026, for the period ended September 30. The company sells NUPLAZID, approved for Parkinson's disease psychosis, and DAYBUE, the first approved treatment for Rett syndrome. Management credited strong uptake of DAYBUE STIX, a newer form of the product, for the 39% rise in DAYBUE sales. The adjusted comparison strips out a change in estimate tied to NUPLAZID rebate accruals recorded in 2025, which the company reconciles in a table. On that basis NUPLAZID grew 12%, and the company pointed to underlying Demand and a wider commercial reach. DAYBU, the European Union version, launched in Germany in early October 2026 after approval in August.

Why Net Income Fell Despite Higher Operating Profit

Income from operations rose to USD 71.7 million from USD 35.8 million, so the lower Bottom Line did not come from the core business. The difference was tax: Acadia recorded an income tax expense of USD 26.9 million this quarter against a benefit of USD 27.2 million a year earlier, which cut net income to USD 53.5 million from USD 71.8 million. Selling, general and administrative expenses rose to USD 159 million from USD 133 million, while Research and Development spending fell to USD 76 million from USD 88 million. For the nine months, revenue was USD 918.3 million and net income USD 88.7 million, or USD 0.51 per diluted share. Cash and Investment securities stood at USD 976 million, compared with USD 820 million at December 31, 2025.

Revised Guidance and the Remlifanserin Data Calendar

Besides the DAYBUE lift, Acadia narrowed NUPLAZID guidance to USD 760 to 775 million from USD 760 to 790 million. It lowered its research and development outlook to USD 325 to 340 million from USD 355 to 380 million, and set selling, general and administrative expenses at USD 665 to 685 million. Pipeline events matter for the next stage: additional Phase 2 RADIANT data on remlifanserin in Alzheimer's disease psychosis will be presented on November 17, 2026, in Boston. The company expects two Phase 2 readouts in 2027, ACP-211 in major depressive disorder in the second half and remlifanserin in Lewy body dementia psychosis in the fourth quarter. Clinical results can disappoint, and the company says it is still looking for a Japan distribution partner.

Where Things Stand

Sales momentum, not weak earnings, is the main message. Acadia Pharmaceuticals (NASDAQ:ACAD) grew DAYBUE sales 39% and Operating Income roughly doubled, while the drop in diluted Earnings to USD 0.31 largely reflects a swing from a tax benefit to a tax expense. The higher DAYBUE outlook and a cash balance of USD 976 million give it room to fund trials, though rising selling costs and pipeline readouts remain risks. Next markers are the November 17 data presentation and the 2027 Phase 2 results.